High-cost Gilead cell therapy proves durable for some lymphoma patients
SAN DIEGO (Reuters) – Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc’s Yescarta were still responding to the cell therapy after at least two years of follow-up, the company said on Sunday. FILE PHOTO: A Gilead Sciences, Inc. office is shown in Foster City, California, U.S. May 1,… Read More »